4066
J. Gao et al. / Tetrahedron 66 (2010) 4063–4067
4.4. General procedure for the TMG-catalyzed reaction of CO2
and 2-aminobenzonitrile
128.9, 139.2, 141.8, 150.0, 162.0; ESI-MS calcd for C8H5ClN2O2
196.59, found 195.21(MꢁH)ꢁ.
In a typical experiment, to a 50 mL stainless steel autoclave
with an inner glass tube were charged with 2-amino-
benzonitriles (5 mmol) and guanidine base (0.25 mmol). A cer-
tain amount of CO2 was introduced into the autoclave and then
the autoclave was heated to the reaction temperature. Then CO2
pressure was adjusted to the desired value and the reaction was
run under stirring for desired time. After completion of reaction,
the autoclave was allowed to be cooled in an ice bath and CO2
was slowly vented. The residue was treated with 1 N HCl (30 mL),
washed with tert-butyl methyl ether (20 mL) and dried under
vacuum at 60 ꢀC for 4 h to afford the desired product. The
products were further identified by NMR and MS (see the
Supplementary data), which are consistent with those reported
in the literature13c,16c and in good agreement with the assigned
structures. The NMR charts for the products and guanidines
G1–G3 were given in Supplementary data.
4.6.3. 6-Chloroquinazoline-2, 4(1H,3H)-dione (2d). White solid.
Mp>300 ꢀC (lit.16c >300 ꢀC). IR (KBr) 3198, 3058, 1711, 1668, 1483,
1428, 1284, 877 cmꢁ1 1H NMR (400 MHz, DMSO-d6):
; d 7.17 (d,
3J¼8.8 Hz, 1H), 7.68 (d, 3J¼8.8 Hz, 1H), 7.81 (s, 1H), 11.32 (s, 2H); 13
C
NMR (100.6 MHz, DMSO-d6) d 115.7, 117.5, 125.8, 126.1, 134.6, 139.7,
150.0, 161.7; ESIMS calcd for C8H5ClN2O2 196.59, found 195.17
(MꢁH)ꢁ.
4.6.4. 6-Bromoquinazoline-2,4(1H,3H)-dione (2e). White solid.
Mp>300 ꢀC (lit.13c >300 ꢀC). IR (KBr) 3193, 3066, 1742, 1701, 1613,
1480, 1433,1286, 836 cmꢁ1; 1H NMR (400 MHz, DMSO-d6)
d 7.71 (d,
3J¼8.7 Hz, 1H), 7.78 (dd, 2J¼8.8 Hz, 3J¼2.3 Hz, 1H), 7.93 (d,
3J¼2.3 Hz, 1H), 11.26 (s, 1H), 11.43 (s, 1H); 13C NMR (100.6 MHz,
DMSO-d6)
d 113.7, 116.1, 117.6, 128.8, 137.4, 139.9, 149.9, 161.6;
HRMS: calcd for C8H5BrN2O2 (MꢁH)ꢁ 238.9462, found 238.9455.
4.6.5. 6-Fluoroquinazoline-2,4(1H,3H)-dione
(2f). White solid.
Mp>300 ꢀC. IR (KBr) 3199, 3059, 1714, 1675, 1635, 1500, 1439, 1288,
4.5. Characterization data
884 cmꢁ1
;
1H NMR (400 MHz, DMSO-d6)
d
7.19 (q, 4J¼8.8 Hz, 1H),
7.52–7.60 (m, 2H), 11.20 (s, 1H), 11.41 (s, 1H); 13C NMR (100.6 MHz,
4.5.1. N-(1,3-Dimethylimidazolidin-2-ylidene) butan-1-amine
DMSO-d6) d (111.7, 112.0), (115.2, 115.3), (117.4, 117.5), (122.7, 122.9),
(G1). Colorless liquid. 1H NMR (400 MHz, CDCl3)
d
0.90 (t,
137.4, 150.0, (156.0, 158.4), (162.05, 162.07); HRMS calcd for
3J¼7.2 Hz, 3H), 1.31–1.40 (m, 2H), 1.47–1.55 (m, 2H), 2.77 (s, 6H),
C8H5FN2O2 (MꢁH)ꢁ 179.0262, found 179.0255.
3.12 (s, 4H), 3.32 (t, 3J¼7.2 Hz, 2H); 13C NMR (75 MHz, CDCl3)
d
13.96, 20.32, 35.58, 36.40, 47.20, 49.40, 156.88; ESI-MS calcd for
Acknowledgements
C9H19N3 169.27, found 170.39 (MþH)þ.
Financial support by the National Natural Science Foundation of
China (Grants Nos. 20672054, 20872073), and Research Fellowship
for International Young Scientists from NSFC (20950110325), the
111 project (B06005), and the Committee of Science and Technol-
ogy of Tianjin is gratefully acknowledged.
4.5.2. N-(1,3-Dimethylimidazolidin-2-ylidene)
cyclohexanamine
1.15–1.72 (m,
(G2). Colorless liquid. 1H NMR (400 MHz, CDCl3)
d
10H), 2.76 (s, 6H), 3.11 (s, 4H), 3.38–3.43 (m, 1H); 13C NMR
(100.6 MHz, CDCl3) d 25.2, 25.8, 31.3, 36.5, 44.9, 54.0, 155.4; ESI-MS
calcd for C11H21N3 195.30, found 196.26 (MþH)þ; HRMS: calcd for
C11H21N3 (MþH)þ 196.1808, found 196.1804.
Supplementary data
4.5.3. 2-Butyl-1,1,3,3-tetramethylguanidine (G3). Colorless liquid.
1H NMR (400 MHz, CDCl3)
d
0.89 (t, 3J¼7.4 Hz, 3H), 1.28–1.37 (m,
Supplementary data associated with this article can be found in
clude MOL files and InChIKeys of the most important compounds
described in this article.
2H), 1.46–1.53 (m, 2H), 2.64 (s, 6H), 2.73 (s, 6H), 3.09 (t, 3J¼7.4 Hz,
2H); 13C NMR (75 MHz, CDCl3)
d 13.7, 20.3, 34.6, 38.6, 39.0, 39.4,
48.8, 159.7; ESI-MS calcd for C9H21N3 171.28, found 172.27 (MþH)þ.
References and notes
4.6. Quinazoline-2,4(1H, 3H)-dione (2a)
1. Tran, T. P.; Ellsworth, E. L.; Stier, M. A.; Domagala, J. M.; Showalter, H. D. H.;
Gracheck, S. J.; Shapiro, M. A.; Joannides, T. E.; Singh, R. Bioorg. Med. Chem. Lett.
2004, 14, 4405–4409.
2. Hayao, S.; Havera, H. J.; Strycker, W. G.; Leipzig, T. J.; Kulp, R. A.; Hartzler, H. E.
J. Med. Chem. 1965, 8, 807–815.
3. (a) Kakuta, H.; Tanatani, A.; Nagasawa, K.; Hashimoto, Y. Chem. Pharm. Bull.
2003, 51, 1273–1282; (b) Boyles, D. C.; Curran, T. T.; Parlett, R. V. Org. Process Res.
Dev. 2002, 6, 230–233.
4. Meuldermans, W.; Hendrickx, J.; Woestenborghs, R.; van Peer, A.; Lauwers, W.;
De Cree, J.; Heykants, J. Arzneim. -Forsch. 1988, 38, 789–794.
White solid. Mp>300 ꢀC (lit.16c >300 ꢀC). IR (KBr) 3253, 3054,
2846, 1702, 1670, 1618, 1443, 755 cmꢁ1; 1H NMR (300 MHz, DMSO-
d6)
d
7.14–7.19 (m, 2H), 7.63 (t, 3J¼7.7 Hz, 1H), 7.88 (d, 3J¼7.7 Hz,1H),
11.13 (s, 1H), 11.27 (s, 1H); 13C NMR (100.6 MHz, DMSO-d6)
d
114.2,
115.2, 122.2, 126.9, 134.8, 140.8, 150.2, 162.7; ESI-MS calcd for
C8H6N2O2 162.15, found 161.17(MꢁH)ꢁ.
5. (a) Imagawa, J.; Sakai, K. Eur. J. Pharmacol. 1986, 131, 257–264; (b) Russell, R. K.;
Press, J. B.; Rampulla, R. A.; McNally, J. J.; Falotico, R.; Keiser, J. A.; Bright, D. A.;
Tobia, A. J. Med. Chem. 1988, 31, 1786–1793; (c) Russo, F.; Romeo, G.; Guccione,
S.; De Blasi, A. J. Med. Chem. 1991, 34, 1850–1854.
4.6.1. 6,7-Dimethoxyquinazoline-2,4(1H, 3H)-dione (2b). Light yel-
low solid. Mp>300 ꢀC (lit.16c >300 ꢀC). IR (KBr) 3471, 3379, 3294,
1708, 1653, 1625, 1467, 1436, 1265, 1099 cmꢁ1 1H NMR (400 MHz,
;
6. (a) Mounetou, E.; Legault, J.; Lacroix, J.; C-Gaudreault, R. J. Med. Chem. 2001, 44,
694–702; (b) Chao, Q.; Deng, L.; Shih, H.; Leoni, L. M.; Genini, D.; Carson, D. A.;
Cottam, H. B. J. Med. Chem. 1999, 42, 3860–3873.
7. (a) Pastor, G.; Blanchard, C.; Montginoul, C.; Torreilles, E.; Giral, L.; Texier, A.
Bull. Soc. Chim. Fr. 1975, 1331–1338; (b) Khalifa, M.; Osman, A. N.; Ibrahim, M.
G.; Ossman, A. R. E.; Ismail, M. A. Pharmazie 1982, 37, 115–117.
DMSO-d6)
d
3.74 (s, 3H), 3.78 (s, 3H), 6.63 (s, 1H), 7.22 (s, 1H), 10.90
55.6, 55.7,
(s, 1H), 11.08 (s, 1H); 13C NMR (100.6 MHz, DMSO-d6)
d
97.6, 106.1, 107.3, 136.4, 144.9, 150.3, 154.8, 162.3; ESI-MS calcd for
C10H10N2O4 222.2, found 221.07(MꢁH)ꢁ.
8. Michman, M.; Patai, S.; Wiesel, Y. Org. Prep. Proced. Int. 1978, 10, 13–16.
9. Lange, N. A.; Sheibley, F. E. Org. Synth. 1943, 2, 79–80.
4.6.2. 7-Chloroquinazoline-2, 4(1H,3H)-dione (2c). Light yellow
solid. Mp>300 ꢀC (lit.16c >300 ꢀC). IR (KBr) 3305, 3047, 1743, 1683,
10. Vorbrueggen, H.; Krolikiewicz, K. Tetrahedron 1994, 50, 6549–6558.
11. (a) Gouilleux, L.; Fehrentz, J. A.; Winternitz, F.; Martinez, J. Tetrahedron Lett.
1996, 37, 7031–7034; (b) Vogtle, M. M.; Marzinzik, A. L. QSAR Comb. Sci. 2004,
23, 440–459; (c) Smith, A. L.; Thomson, C. G.; Leeson, P. D. Bioorg. Med. Chem.
Lett. 1996, 6, 1483–1486; (d) Gordeev, M. F.; Hui, H. C.; Gordon, E. M.; Patel, D. V.
1617, 1430, 1284, 862 cmꢁ1; 1H NMR (400 MHz, DMSO-d6)
d 7.16 (s,
1H), 7.20 (d, 3J¼8.4 Hz, 1H), 7.86 (d, 3J¼7.2 Hz, 1H), 11.25 (s, 1H),
11.41 (s, 1H); 13C NMR (100.6 MHz, DMSO-d6)
d 113.2, 114.5, 122.3,